Global InformationUromune information
| Vaccine description | |
|---|---|
| Target | Bacteria (E. coli, K. pneumoniae, E. faecalis, P. vulgaris) |
| Vaccine type | Inactivated |
| Clinical data | |
| Trade names | Uromune |
| Other names | MV-140; MV140 |
| Routes of administration | Sublingual spray |
| ATC code |
|
Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used in the prevention of recurrent urinary tract infections (UTIs).[1][2][3] In clinical studies, it has been found to reduce total number of UTIs (by ~70%), to increase UTI-free rates (from 25% to ~57%), and to increase time to next UTI (from 48 days to 275 days), as well as to reduce UTI symptoms, reduce antibiotic use, and improve quality of life, over a period of 9 months following treatment.[2][4][5][6] The effectiveness of the vaccine appears to wane with time, which may necessitate readministration.[2][5][6][7] Uromune is used as a sublingual spray once daily for 3 months.[2][3][5]
Side effects of Uromune are considered infrequent, minor, and usually not treatment-related.[2] Uromune is an inactivated combination of four major bacteria known to cause recurrent UTIs, including Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris.[2] It is thought to work by increasing adaptive immunity against UTI-causing bacteria and possibly also by increasing trained immunity against these pathogens.[2][8]
Uromune first became available for clinical use in 2010[2] and was first described in the literature by 2012.[9] It was developed and marketed in Spain by Inmunotek S.L.[1][10][9] Uromune has also been approved in Mexico and the Dominican Republic and is currently pending approval in Canada.[2][11][1] The vaccine is under development for use and is available via special-access programs in numerous other countries, including in many European countries, Australia, New Zealand, and Chile, among others.[1][2][11] Development and approval in the United States is expected to take longer than other countries.[6][11] Uromune is also under investigation for other uses besides prevention of uncomplicated recurrent UTIs in adults, as well as readministration following potential waning effectiveness.[2]
- ^ a b c d "MV 140". Adis Insight. Springer Nature Switzerland AG. Retrieved 15 February 2024.
- ^ a b c d e f g h i j k Nickel JC, Doiron RC (February 2023). "An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women". Pathogens. 12 (3): 359. doi:10.3390/pathogens12030359. PMC 10052183. PMID 36986281.
- ^ a b Nickel JC, Saz-Leal P, Doiron RC (August 2020). "Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future". Can Urol Assoc J. 14 (8): 281–287. doi:10.5489/cuaj.6690. PMC 7402698. PMID 33626320.
- ^ Cite error: The named reference
pmid38319200was invoked but never defined (see the help page). - ^ a b c Cite error: The named reference
pmid31806578was invoked but never defined (see the help page). - ^ a b c Cite error: The named reference
UrologyTimes2021was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid36472057was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid27966556was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
pmid22806485was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid36861882was invoked but never defined (see the help page). - ^ a b c Cite error: The named reference
PharmacyTimes2023was invoked but never defined (see the help page).